BioClonetics Immunotherapeutics

Designing the first cure for HIV through the use of monoclonal antibodies

Heath TX

Technology Healthcare B2C Biotech Service

We have created a cell line that produces an anti-HIV antibody called Clone 3.

We have demonstrated that Clone 3 neutralizes all clades and groups of HIV isolates.

We have identified that Clone 3 targets HIV at an immutable site on the HIV virus.

We expect to complete animal trials within 18 to 24 months.

We are working with several world-class laboratories who will assist us in conducting the next steps of our plan.

1.2 million estimated people die from HIV each year.

2 million estimated people are infected with HIV each year.